Most small companies outsource manufacturing to firms that specialize in it, although ARNA set up their own facility to manufacture a similar drug. Maybe ACAD should talk to ARNA about Mfg? It's not a big deal and should not be expensive relative to their high levels of cash. Pima is a small molecule (relatively simple to mfg), not a biologic (complex to mfg).
I am not so sure about them needing more cash (assuming they don't buy another company which I think is highly unlikely at this time). They indicated recently they have enough cash to take them into 2017. I believe they expressed this two different times.
As I understand it, the stability testing is using the batches that will ultimately be used to issue product to the market, and so, they have already have an unknown amount of product in stock. I don't expect manufacturing of further batches would be a critical path item, in terms of the overall plan to get the product to market.
Once the FDA accepts the NDA, I expect they could then place further orders on the manufacturer to produce further batches, with a commitment from the manufacturer, that they'd be turned around quickly enough to ensure they had sufficient supply for launch....at least that's what I'd be considering.